Loading…
Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains
The objective of this work was to evaluate the efficacy of rifampin, and its combinations with imipenem or sulbactam, in an experimental pneumonia model caused by two panresistant Acinetobacter baumannii strains (HUVR99 and HUVR113). Minimum inhibitory concentrations (MICs) and minimal bactericidal...
Saved in:
| Published in: | European journal of clinical microbiology & infectious diseases 2011-07, Vol.30 (7), p.895-901 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c475t-82b09f7fe153438f08464486dea88613f5306fa64b168b98e9d3eb01dfd731523 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c475t-82b09f7fe153438f08464486dea88613f5306fa64b168b98e9d3eb01dfd731523 |
| container_end_page | 901 |
| container_issue | 7 |
| container_start_page | 895 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 30 |
| creator | Pachón-Ibáñez, M. E. Docobo-Pérez, F. Jiménez-Mejias, M. E. Ibáñez-Martínez, J. García-Curiel, A. Pichardo, C. Pachón, J. |
| description | The objective of this work was to evaluate the efficacy of rifampin, and its combinations with imipenem or sulbactam, in an experimental pneumonia model caused by two panresistant
Acinetobacter baumannii
strains (HUVR99 and HUVR113). Minimum inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) (μg/ml) of the strains were rifampin 128/>128 for both strains, imipenem 128/>256 and 256/>256 for HUVR99 and HUVR113, respectively, and sulbactam >256/>256 for both strains. In time–kill studies, at MICs, rifampin was bactericidal for both strains and sulbactam against the HUVR99 strain. Rifampin plus imipenem or sulbactam, at the MIC or mice
C
max
, were synergistic. In vivo, against HUVR99 and HUVR113, rifampin (73% and 40%) and its combinations improved the survival with respect to the control group (20% and 0%,
p
|
| doi_str_mv | 10.1007/s10096-011-1173-6 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_907164815</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>869592084</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-82b09f7fe153438f08464486dea88613f5306fa64b168b98e9d3eb01dfd731523</originalsourceid><addsrcrecordid>eNqFkc2K1TAYhoMozpnRC3AjQZDZWE2aNEmXwzD-wIAbXZev6RfN0CY1ScFzK16tOZ6jA4K4SSB53jc_DyHPOHvNGdNvch171TDOG861aNQDsuNSdI0UWjwkO9YL2fS6FWfkPOc7VjNG68fkrOVCqE6aHflx45y3YPc0Opq8g2X14RX1gS4xxPIVE6x7CmE6LNm4jD5A8THkXwwEit9XTH7BUGCmy5Z8QLoG3GrcQy2ZcKYWtowTHfd0hZAw-1wgFHplK1ziCLZgoiNsC4TgPc0lgQ_5CXnkYM749DRfkM9vbz5dv29uP777cH1121ipu9KYdmS90w55J6QwjhmppDRqQjBGceE6wZQDJUeuzNgb7CeBI-OTm7TgXSsuyOWxd03x24a5DIvPFucZAsYtDz3TXElT6_9HGtV3fVsvUMkXf5F3cUuhPuMAcVYFqQrxI2RTzDmhG9b6k5D2A2fDQfBwFDxUwcNB8HDIPD8Vb-OC05_Eb6MVeHkCIFuYXYJgfb7nZKs7oXTl2iOX61b4gun-hv8-_SdWML8x</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>869104376</pqid></control><display><type>article</type><title>Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains</title><source>Springer Link</source><creator>Pachón-Ibáñez, M. E. ; Docobo-Pérez, F. ; Jiménez-Mejias, M. E. ; Ibáñez-Martínez, J. ; García-Curiel, A. ; Pichardo, C. ; Pachón, J.</creator><creatorcontrib>Pachón-Ibáñez, M. E. ; Docobo-Pérez, F. ; Jiménez-Mejias, M. E. ; Ibáñez-Martínez, J. ; García-Curiel, A. ; Pichardo, C. ; Pachón, J.</creatorcontrib><description>The objective of this work was to evaluate the efficacy of rifampin, and its combinations with imipenem or sulbactam, in an experimental pneumonia model caused by two panresistant
Acinetobacter baumannii
strains (HUVR99 and HUVR113). Minimum inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) (μg/ml) of the strains were rifampin 128/>128 for both strains, imipenem 128/>256 and 256/>256 for HUVR99 and HUVR113, respectively, and sulbactam >256/>256 for both strains. In time–kill studies, at MICs, rifampin was bactericidal for both strains and sulbactam against the HUVR99 strain. Rifampin plus imipenem or sulbactam, at the MIC or mice
C
max
, were synergistic. In vivo, against HUVR99 and HUVR113, rifampin (73% and 40%) and its combinations improved the survival with respect to the control group (20% and 0%,
p
< 0.05), respectively. Rifampin (87% and 46%) and its combinations improved the sterilization of blood cultures with respect to the control groups (0%,
p
< 0.05). In regard to the bacterial clearance from lungs, rifampin (2.57 ± 2.47 and 5.35 ± 3.03 log
10
cfu/g) and its combinations with imipenem or sulbactam diminished the bacterial lung concentration with respect to the control group (10.89 ± 3.00 and 11.86 ± 0.49,
p
< 0.05) with both strains. In conclusion, rifampin alone or associated to imipenem or sulbactam were effective for the treatment of murine pneumonia caused by selected panresistant
A. baumannii
strains.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-011-1173-6</identifier><identifier>PMID: 21336548</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Acinetobacter baumannii ; Acinetobacter baumannii - drug effects ; Animals ; Anti-Bacterial Agents - administration & dosage ; Antibacterial agents ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial Load ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Disease Models, Animal ; Drug dosages ; Drug Resistance, Multiple, Bacterial ; Drug Therapy, Combination - methods ; Experiments ; Female ; Imipenem - administration & dosage ; Imipenem - pharmacology ; Infections ; Infectious diseases ; Internal Medicine ; Lung - microbiology ; Medical Microbiology ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Microbial Sensitivity Tests ; Microbial Viability - drug effects ; Pharmacology. Drug treatments ; Pneumology ; Pneumonia ; Pneumonia, Bacterial - drug therapy ; Respiratory system : syndromes and miscellaneous diseases ; Ribosomal DNA ; Rifampin - administration & dosage ; Rifampin - pharmacology ; Rodent Diseases - drug therapy ; Sterilization ; Sulbactam - administration & dosage ; Sulbactam - pharmacology ; Treatment Outcome</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2011-07, Vol.30 (7), p.895-901</ispartof><rights>Springer-Verlag 2011</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-82b09f7fe153438f08464486dea88613f5306fa64b168b98e9d3eb01dfd731523</citedby><cites>FETCH-LOGICAL-c475t-82b09f7fe153438f08464486dea88613f5306fa64b168b98e9d3eb01dfd731523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24275367$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21336548$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pachón-Ibáñez, M. E.</creatorcontrib><creatorcontrib>Docobo-Pérez, F.</creatorcontrib><creatorcontrib>Jiménez-Mejias, M. E.</creatorcontrib><creatorcontrib>Ibáñez-Martínez, J.</creatorcontrib><creatorcontrib>García-Curiel, A.</creatorcontrib><creatorcontrib>Pichardo, C.</creatorcontrib><creatorcontrib>Pachón, J.</creatorcontrib><title>Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>The objective of this work was to evaluate the efficacy of rifampin, and its combinations with imipenem or sulbactam, in an experimental pneumonia model caused by two panresistant
Acinetobacter baumannii
strains (HUVR99 and HUVR113). Minimum inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) (μg/ml) of the strains were rifampin 128/>128 for both strains, imipenem 128/>256 and 256/>256 for HUVR99 and HUVR113, respectively, and sulbactam >256/>256 for both strains. In time–kill studies, at MICs, rifampin was bactericidal for both strains and sulbactam against the HUVR99 strain. Rifampin plus imipenem or sulbactam, at the MIC or mice
C
max
, were synergistic. In vivo, against HUVR99 and HUVR113, rifampin (73% and 40%) and its combinations improved the survival with respect to the control group (20% and 0%,
p
< 0.05), respectively. Rifampin (87% and 46%) and its combinations improved the sterilization of blood cultures with respect to the control groups (0%,
p
< 0.05). In regard to the bacterial clearance from lungs, rifampin (2.57 ± 2.47 and 5.35 ± 3.03 log
10
cfu/g) and its combinations with imipenem or sulbactam diminished the bacterial lung concentration with respect to the control group (10.89 ± 3.00 and 11.86 ± 0.49,
p
< 0.05) with both strains. In conclusion, rifampin alone or associated to imipenem or sulbactam were effective for the treatment of murine pneumonia caused by selected panresistant
A. baumannii
strains.</description><subject>Acinetobacter baumannii</subject><subject>Acinetobacter baumannii - drug effects</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacterial Load</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Disease Models, Animal</subject><subject>Drug dosages</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Drug Therapy, Combination - methods</subject><subject>Experiments</subject><subject>Female</subject><subject>Imipenem - administration & dosage</subject><subject>Imipenem - pharmacology</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Internal Medicine</subject><subject>Lung - microbiology</subject><subject>Medical Microbiology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbial Viability - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Pneumonia</subject><subject>Pneumonia, Bacterial - drug therapy</subject><subject>Respiratory system : syndromes and miscellaneous diseases</subject><subject>Ribosomal DNA</subject><subject>Rifampin - administration & dosage</subject><subject>Rifampin - pharmacology</subject><subject>Rodent Diseases - drug therapy</subject><subject>Sterilization</subject><subject>Sulbactam - administration & dosage</subject><subject>Sulbactam - pharmacology</subject><subject>Treatment Outcome</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFkc2K1TAYhoMozpnRC3AjQZDZWE2aNEmXwzD-wIAbXZev6RfN0CY1ScFzK16tOZ6jA4K4SSB53jc_DyHPOHvNGdNvch171TDOG861aNQDsuNSdI0UWjwkO9YL2fS6FWfkPOc7VjNG68fkrOVCqE6aHflx45y3YPc0Opq8g2X14RX1gS4xxPIVE6x7CmE6LNm4jD5A8THkXwwEit9XTH7BUGCmy5Z8QLoG3GrcQy2ZcKYWtowTHfd0hZAw-1wgFHplK1ziCLZgoiNsC4TgPc0lgQ_5CXnkYM749DRfkM9vbz5dv29uP777cH1121ipu9KYdmS90w55J6QwjhmppDRqQjBGceE6wZQDJUeuzNgb7CeBI-OTm7TgXSsuyOWxd03x24a5DIvPFucZAsYtDz3TXElT6_9HGtV3fVsvUMkXf5F3cUuhPuMAcVYFqQrxI2RTzDmhG9b6k5D2A2fDQfBwFDxUwcNB8HDIPD8Vb-OC05_Eb6MVeHkCIFuYXYJgfb7nZKs7oXTl2iOX61b4gun-hv8-_SdWML8x</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Pachón-Ibáñez, M. E.</creator><creator>Docobo-Pérez, F.</creator><creator>Jiménez-Mejias, M. E.</creator><creator>Ibáñez-Martínez, J.</creator><creator>García-Curiel, A.</creator><creator>Pichardo, C.</creator><creator>Pachón, J.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20110701</creationdate><title>Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains</title><author>Pachón-Ibáñez, M. E. ; Docobo-Pérez, F. ; Jiménez-Mejias, M. E. ; Ibáñez-Martínez, J. ; García-Curiel, A. ; Pichardo, C. ; Pachón, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-82b09f7fe153438f08464486dea88613f5306fa64b168b98e9d3eb01dfd731523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acinetobacter baumannii</topic><topic>Acinetobacter baumannii - drug effects</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacterial Load</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Disease Models, Animal</topic><topic>Drug dosages</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Drug Therapy, Combination - methods</topic><topic>Experiments</topic><topic>Female</topic><topic>Imipenem - administration & dosage</topic><topic>Imipenem - pharmacology</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Internal Medicine</topic><topic>Lung - microbiology</topic><topic>Medical Microbiology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbial Viability - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Pneumonia</topic><topic>Pneumonia, Bacterial - drug therapy</topic><topic>Respiratory system : syndromes and miscellaneous diseases</topic><topic>Ribosomal DNA</topic><topic>Rifampin - administration & dosage</topic><topic>Rifampin - pharmacology</topic><topic>Rodent Diseases - drug therapy</topic><topic>Sterilization</topic><topic>Sulbactam - administration & dosage</topic><topic>Sulbactam - pharmacology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pachón-Ibáñez, M. E.</creatorcontrib><creatorcontrib>Docobo-Pérez, F.</creatorcontrib><creatorcontrib>Jiménez-Mejias, M. E.</creatorcontrib><creatorcontrib>Ibáñez-Martínez, J.</creatorcontrib><creatorcontrib>García-Curiel, A.</creatorcontrib><creatorcontrib>Pichardo, C.</creatorcontrib><creatorcontrib>Pachón, J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pachón-Ibáñez, M. E.</au><au>Docobo-Pérez, F.</au><au>Jiménez-Mejias, M. E.</au><au>Ibáñez-Martínez, J.</au><au>García-Curiel, A.</au><au>Pichardo, C.</au><au>Pachón, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>30</volume><issue>7</issue><spage>895</spage><epage>901</epage><pages>895-901</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>The objective of this work was to evaluate the efficacy of rifampin, and its combinations with imipenem or sulbactam, in an experimental pneumonia model caused by two panresistant
Acinetobacter baumannii
strains (HUVR99 and HUVR113). Minimum inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) (μg/ml) of the strains were rifampin 128/>128 for both strains, imipenem 128/>256 and 256/>256 for HUVR99 and HUVR113, respectively, and sulbactam >256/>256 for both strains. In time–kill studies, at MICs, rifampin was bactericidal for both strains and sulbactam against the HUVR99 strain. Rifampin plus imipenem or sulbactam, at the MIC or mice
C
max
, were synergistic. In vivo, against HUVR99 and HUVR113, rifampin (73% and 40%) and its combinations improved the survival with respect to the control group (20% and 0%,
p
< 0.05), respectively. Rifampin (87% and 46%) and its combinations improved the sterilization of blood cultures with respect to the control groups (0%,
p
< 0.05). In regard to the bacterial clearance from lungs, rifampin (2.57 ± 2.47 and 5.35 ± 3.03 log
10
cfu/g) and its combinations with imipenem or sulbactam diminished the bacterial lung concentration with respect to the control group (10.89 ± 3.00 and 11.86 ± 0.49,
p
< 0.05) with both strains. In conclusion, rifampin alone or associated to imipenem or sulbactam were effective for the treatment of murine pneumonia caused by selected panresistant
A. baumannii
strains.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>21336548</pmid><doi>10.1007/s10096-011-1173-6</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 2011-07, Vol.30 (7), p.895-901 |
| issn | 0934-9723 1435-4373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_907164815 |
| source | Springer Link |
| subjects | Acinetobacter baumannii Acinetobacter baumannii - drug effects Animals Anti-Bacterial Agents - administration & dosage Antibacterial agents Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial Load Biological and medical sciences Biomedical and Life Sciences Biomedicine Disease Models, Animal Drug dosages Drug Resistance, Multiple, Bacterial Drug Therapy, Combination - methods Experiments Female Imipenem - administration & dosage Imipenem - pharmacology Infections Infectious diseases Internal Medicine Lung - microbiology Medical Microbiology Medical sciences Mice Mice, Inbred C57BL Microbial Sensitivity Tests Microbial Viability - drug effects Pharmacology. Drug treatments Pneumology Pneumonia Pneumonia, Bacterial - drug therapy Respiratory system : syndromes and miscellaneous diseases Ribosomal DNA Rifampin - administration & dosage Rifampin - pharmacology Rodent Diseases - drug therapy Sterilization Sulbactam - administration & dosage Sulbactam - pharmacology Treatment Outcome |
| title | Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A36%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20rifampin,%20in%20monotherapy%20and%20in%20combinations,%20in%20an%20experimental%20murine%20pneumonia%20model%20caused%20by%20panresistant%20Acinetobacter%20baumannii%20strains&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Pach%C3%B3n-Ib%C3%A1%C3%B1ez,%20M.%20E.&rft.date=2011-07-01&rft.volume=30&rft.issue=7&rft.spage=895&rft.epage=901&rft.pages=895-901&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-011-1173-6&rft_dat=%3Cproquest_cross%3E869592084%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-82b09f7fe153438f08464486dea88613f5306fa64b168b98e9d3eb01dfd731523%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=869104376&rft_id=info:pmid/21336548&rfr_iscdi=true |